Convenient measurement of systolic pressure: the reliability and validity of manual radial pulse pressure measurement.

BACKGROUND: It is important to assess a patient's medical condition noninvasively, particularly in hospice care settings. OBJECTIVE: The aim of this study was to investigate the reliability of manually measuring the radial pulse pressure and its validity for predicting the systolic blood pressure. DESIGN: An observational study consisting of two phases: a reliability study and a validity study. SETTING/SUBJECTS: Patients admitted to a palliative care unit. MEASUREMENTS: To assess the interrater reliability, the radial pulse pressure was prospectively measured independently by a physician and nurse using a three-level assessment (impalpable, weak, and normal) in 43 patients admitted to a palliative care unit. To assess the validity, we analyzed a total of 156 patients, consisting of the prospectively collected patients and 113 patients retrospectively recruited. Radial pulse and systolic blood pressures were recorded on admission. We calculated the sensitivity and specificity of the radial pulse pressure to predict a systolic blood pressure of 90 mm Hg or more. RESULTS: The κ coefficient of the physician and nurse was 0.788. The sensitivity and specificity to predict a systolic blood pressure of 90 mm Hg or more using the cutoff point of a normal versus weak/impalpable radial pulse pressure were 84% (95% confidence intervals, 77-89) and 82% (52-96), respectively. CONCLUSIONS: Manually measuring the radial pulse pressure is reliable and can be used to indicate a systolic blood pressure of 90 mm Hg or more.

Treatable complications of cancer patients referred to an in-patient hospice.

This paper illustrates the importance of accurate diagnoses and treatments of complications in terminally ill cancer patients. The paper reports on five hospice in-patients who completely recovered from life-threatening complications; three of them had been incorrectly labeled as "imminently dying" by the referring physicians. The paper concludes that it would be beneficial for patients to receive examinations and a trial of medical treatment in their continuing treatment settings.

Agitated terminal delirium and association with partial opioid substitution and hydration.

BACKGROUND: Delirium is often a distressing symptom for both patients and their families, and its prevention is important. The primary aim of this study was to clarify the effects of partial opioid substitution and hydration on the occurrence of agitated delirium in the final stage of cancer. METHODS: An historical control study on consecutive terminally ill cancer patients admitted to a palliative care unit (164 in 1996-1997 and 120 in 2000-2001). In 2000-2001, we actively performed hydration and partial opioid substitution from morphine with fentanyl on individual grounds. Two independent raters evaluated the degree of agitation and cognitive impairment during the final week, using the Memorial Delirium Assessment Scale, the Agitation Distress Scale, the Communication Capacity Scale, and a consciousness scale. RESULTS: Compared to 1996-1997, in 2000-2001, the use of artificial hydration (33% to 44%, p = 0.053) and opioid rotation (3.0% to 41%, p < 0.01) increased, while there were no statistically significant differences in hydration volume, the mean dose, and the high-dose requirements of morphine. The prevalence of agitated delirium, the agitation score, the percentage of patients achieving clear-complex communication, and the percentage of patients who maintained clear consciousness did not significantly change. CONCLUSIONS: Partial opioid substitution with fentanyl and moderate levels of hydration had no significant preventive effects on the occurrence of agitated delirium in the last week on a mass level. We should explore new strategies to prevent agitated delirium that are practically available in Japan.

Impaired communication capacity and agitated delirium in the final week of terminally ill cancer patients: prevalence and identification of research focus.

The maintenance of intellectual activity is an important area in the "good death" concept. To clarify the communication capacity levels of terminally ill cancer patients in their final week, and to identify factors contributing to the development of communication capacity impairment and agitated delirium, a retrospective study was performed on 284 consecutive hospice inpatients. The data were collected by chart review, and two independent raters measured the degree of communication capacity and agitation in the last week, using multiple items from the Memorial Delirium Assessment Scale, the Communication Capacity Scale, and the Agitation Distress Scale. The percentages of patients who could achieve complex communication were 43%, 28%, and 13% at 5 days, 3 days, and 1 day before death, respectively. Agitated delirium was identified in 20%. Patients receiving opioids at a dose of > or =120 mg oral morphine equivalents/day one week before death were significantly unable to communicate clearly 3 days before death (0.48 [0.28-0.84], P=0.011). Male gender and the presence of icterus were identified as significant contributors to the development of agitated delirium (odds ratios [95% C.I.]=2.6 [1.4-5.0], P<0.01; 2.4 [1.3-4.4], P< 0.01). These findings demonstrate that communication capacity impairment and agitated delirium are frequently observed in terminally ill cancer patients, and are significantly correlated with a higher dose requirement of opioids and the presence of icterus. To explore the best management to maintain the intellectual activity of dying patients, research should focus on a homogeneous sample of patients receiving high-dose opioids and those with hepatic encephalopathy. In the meanwhile, clinicians should educate patients and family members about the nature of the dying process and help facilitate the completion of life purposes requiring complex mental activities before the latest stages of cancer.

Correlation of the dose of midazolam for symptom control with administration periods: the possibility of tolerance.

Although tolerance to midazolam is sometimes described in the palliative care literature, no studies have systemically examined the possibility. To explore the association between midazolam dose for symptom palliation and the administration period, a retrospective study was performed on 62 terminally ill cancer patients who required parenteral midazolam in the final three days of life. The mean maximum dose and administration period of midazolam were 38 +/- 45 mg/day (median = 24) and 10 +/- 19 days (median = 2.5), respectively. Thirteen patients (21%) received midazolam at a dose of 60 mg/day or more, and 13 patients (21%) received it for 14 days or longer. The maximum doses were significantly correlated with patient age (rho = -0.32, P = 0.012) and the administration period (rho = 0.47, P < 0.01); and were significantly higher in patients who received midazolam for 14 days or longer (74 +/- 63 mg/day vs. 28 +/- 34 mg/day, P < 0.01). Multivariate analyses revealed that younger age (< or =70) and longer administration periods (> or =14 days) were independent determinants for a midazolam requirement of 60 mg/day or more (odds ratios [95% C.I.] = 0.091 [0.009 - 0.92], P = 0.042; 11 [2.3 - 54], P < 0.01; respectively). The significant correlation of midazolam doses with administration period suggests that the longer use of midazolam can result in the development of tolerance. This finding suggests that midazolam should be reserved for patients with limited prognoses.

Fluid status of terminally ill cancer patients with intestinal obstruction: an exploratory observational study.

Although the dehydration-rehydration problem in end-of-life care is one of the most important issues, clinical indications of hydration therapy have not been clarified because the pathophysiology is poorly understood. To explore the physiological changes of fluid status in terminally ill cancer patients, a prospective observational study was performed. We obtained 9 pairs of blood samplings from hospice inpatients with irreversible bowel obstruction who underwent two or more laboratory examinations during the admission periods. The plasma renin activity (PRA) and brain natriuretic peptide (BNP) were measured, in addition to basic laboratory tests performed as clinically required. A chart review evaluated the degree of fluid retention symptoms. In 7 patients receiving intravenous rehydration of 700-2200 ml/day, the mean PRA level significantly increased from 3.5+/-2.5 ng ml(-1) h(-1) to 11+/-8.2 ng ml(-1) x h(-1) ( P=0.047), and the mean BNP level significantly decreased from 52+/-34 pg/ml to 22+/-14 pg/ml ( P=0.047). Edema, ascites, and pleural effusion/pulmonary edema deteriorated in 5, 3, and 5 patients, respectively. In 2 patients without rehydration therapy, peripheral edema deteriorated with increased PRA levels (0.5 to 20 ng ml(-1) x h(-1), 0.4 to 8.7 ng ml(-1) x h(-1), respectively). In conclusion, intravenous volume depletion with fluid retention symptoms was observed in terminally ill cancer patients with intestinal obstruction both receiving and not receiving intravenous hydration. The pathological mechanism hypothesized is the fluid shift from the intravascular compartment to the interstitial spaces.

Increased plasma morphine metabolites in terminally ill cancer patients with delirium: an intra-individual comparison.

Delirium often causes severe distress for terminally ill cancer patients, and treatment of underlying pathologies is important to achieve symptom alleviation. Although accumulation of morphine metabolites may play an important role in development of delirium, empirical findings are conflicting due to a large inter-individual variation in morphine-related concentrations. To explore intra-individual changes of morphine metabolite concentrations before and after occurrence of terminal delirium, a prospective observational study was performed on terminally ill cancer patients. Among 131 consecutive hospice inpatients, 16 samples from 8 patients who received two blood samplings before and after development of delirium were analyzed. Delirium developed a median of 5 days before death, and clinical causes were attributed to multi-organ failure. Plasma concentrations of morphine-6-glucuronide (M-6-G) and morphine-3-glucuronide (M-3-G) significantly increased after development of delirium within the same patient. Mean normalized concentrations of M-6-G and M-3-G elevated from 1.24 +/- 1.06 to 2.94 +/- 3.52 ng/mL/mg (P = 0.016), and from 7.46 +/- 4.75 to 15.4 +/- 13.2 ng/mL/mg (P = 0.016), respectively. Normalized morphine concentration increased with a marginal statistical significance from 0.54 +/- 0.27 to 0.83 +/- 0.22 ng/mL/mg (P = 0.055). In conclusion, plasma concentrations of M-6-G and M-3-G were significantly higher after development of terminal delirium than before. It is suggested that accumulations of morphine metabolites can contribute to development of delirium in cancer patients whose death is impending.